Document Detail


Cdc20: a potential novel therapeutic target for cancer treatment.
MedLine Citation:
PMID:  23151139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Anaphase Promoting Complex (APC) has been characterized to play pivotal roles in regulating the timely cell cycle progression by forming two functionally distinct E3 ubiquitin ligase sub-complexes, APC(Cdc20) and APC(Cdh1). Interestingly, recent studies have shown that Cdh1 is functioning as a tumor suppressor whereas Cdc20 may function as an oncoprotein to promote the development and progression of human cancers. In this review, we will discuss the physiological role of Cdc20 and its downstream substrates in vitro and in the transgenic mouse model reminiscent of the pathogenesis of human cancers. Furthermore, we summarize recent findings to indicate that Cdc20 may represent a promising therapeutic target, thus development of Cdc20 inhibitors could be useful for achieving better treatment outcome of cancer patients.
Authors:
Zhiwei Wang; Lixin Wan; Jiateng Zhong; Hiroyuki Inuzuka; Pengda Liu; Fazlul H Sarkar; Wenyi Wei
Related Documents :
19021749 - Interleukin-1 in reproductive strategies.
22561519 - Detectable clonal mosaicism and its relationship to aging and cancer.
24204789 - Functional genetic polymorphisms in pp2a subunit genes confer increased risks of lung c...
22879839 - Gynecological cancer age groups at the "dr. salvator vuia" clinical obstetrics and gyne...
22817869 - Is there a future for prenyltransferase inhibitors in cancer therapy?
24302179 - Different expression of p16ink4a and p14arf in cervical and lung cancers.
18386139 - Cancer risk in a cohort of patients with systemic lupus erythematosus (sle) in california.
23377969 - The p53/microrna network in cancer: experimental and bioinformatics approaches.
21576779 - Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  19     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2013  
Date Detail:
Created Date:  2013-04-25     Completed Date:  2013-10-28     Revised Date:  2014-05-13    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  3210-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anaphase-Promoting Complex-Cyclosome
Animals
Antineoplastic Agents / pharmacology*
Cadherins / metabolism
Cdc20 Proteins
Cell Cycle Proteins / metabolism*
Disease Models, Animal
Drug Design
Humans
Mice
Mice, Transgenic
Molecular Targeted Therapy
Neoplasms / drug therapy*,  pathology
Species Specificity
Ubiquitin-Protein Ligase Complexes / metabolism
Grant Support
ID/Acronym/Agency:
GM089763/GM/NIGMS NIH HHS; GM094777/GM/NIGMS NIH HHS; R01 GM089763/GM/NIGMS NIH HHS; R01 GM094777/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/CDH1 protein, human; 0/Cadherins; 0/Cdc20 Proteins; 0/Cell Cycle Proteins; 156288-95-8/CDC20 protein, human; EC 6.3.2.19/Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19/Ubiquitin-Protein Ligase Complexes
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Disease...
Next Document:  When ubiquitin meets NF-?B: a trove for anti-cancer drug development.